Glioblastoma kills quickly. After diagnosis, most people have about 15 months to live. Surgery, chemotherapy, radiation — the standard toolkit has barely budged survival rates in decades, and the side effects are brutal enough that some patients refuse treatment entirely. Now researchers at the University of Virginia say they've found something that might change that equation.
The breakthrough centers on a gene called AVIL. Normally, this gene helps cells maintain their shape and size — routine housekeeping work. But in glioblastoma patients, AVIL gets pushed into overdrive, essentially flipping a switch that allows cancer cells to form and spread through brain tissue. The challenge has always been that once you know what's driving a cancer, stopping it in a lab is one thing. Making it work in an actual human body is another.
Dr. Hui Li's team at UVA identified AVIL as the culprit back in 2020. They proved in mice that blocking the gene's activity could wipe out glioblastoma cells without harming healthy tissue. But the method they used to do that in the lab — inserting genetic material directly — isn't something you can give to a patient. So they set out to find a small molecule that could do the same job in a way that actually works as medicine.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxA Molecule That Crosses the Blood-Brain Barrier
They screened thousands of compounds using a technique called high-throughput screening, essentially running a rapid filter to find candidates worth deeper investigation. What emerged was a molecule that appears to do three things the field has been chasing for years: it blocks AVIL activity specifically in tumor cells, it leaves healthy brain tissue alone, and crucially, it can cross the blood-brain barrier — that protective membrane that keeps most potential neurological drugs from ever reaching the brain.
In mouse experiments published in Science Translational Medicine, the molecule worked without causing harmful side effects. And it could be taken as an oral medication, like a regular prescription pill.
This is not a finish line. The molecule still needs optimization for human use, then extensive testing in volunteers, then FDA review. That process typically takes years. But what makes this different from the incremental tweaks that have defined glioblastoma research is the mechanism itself. Rather than trying to poison cancer cells broadly (and hoping healthy cells survive), this approach targets a specific genetic vulnerability that appears to be fundamental to how glioblastoma forms.
Li has founded a company, AVIL Therapeutics, to develop the inhibitors further. The work was supported by the National Institutes of Health and the Ben & Catherine Ivy Foundation.
For the 14,000 Americans diagnosed with glioblastoma each year, the next phase of this research will determine whether targeting AVIL can finally shift the survival calculus that has barely moved in decades.
